India, Aug. 11 -- Lupin Limited, a global pharmaceutical major, has announced the launch of Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit in the United States.
The product is bioequivalent to Eli Lilly and Company's Glucagon for Injection, 1 mg/vial, and is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. It is also approved as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients.
According to IQVIA MAT (June 2025), Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual U.S. sales of USD 122 million.
Published by HT Digital Content Services with permission fro...